Unique ID issued by UMIN | UMIN000002017 |
---|---|
Receipt number | R000002460 |
Scientific Title | Evaluation of the Intraocular pressure lowering effect of Tafluprost and Latanoprost on normal tension Glaucoma |
Date of disclosure of the study information | 2009/06/15 |
Last modified on | 2012/06/02 15:50:13 |
Evaluation of the Intraocular pressure lowering effect of Tafluprost and Latanoprost on normal tension Glaucoma
Evaluation of the Intraocular pressure lowering effect of Tafluprost and Latanoprost on normal tension Glaucoma
Evaluation of the Intraocular pressure lowering effect of Tafluprost and Latanoprost on normal tension Glaucoma
Evaluation of the Intraocular pressure lowering effect of Tafluprost and Latanoprost on normal tension Glaucoma
Japan |
Glaucoma
Ophthalmology |
Others
NO
To investigate effects of Taflurost and Latanoprost on intraocular pressure and safety in normal-tension glaucoma in randomized, open-labeled, crossover, study
Efficacy
Exploratory
Efficacy: Intraocular Pressure Lowering rate
Safety
Interventional
Cross-over
Randomized
Individual
Open -no one is blinded
Active
NO
NO
Institution is not considered as adjustment factor.
NO
Numbered container method
2
Treatment
Medicine |
Tafluprost monotherapy of 12weeks, Latanoprost monotherapy of 12weeks and if possible, continue monotherapy with either ophthalmic solution for 52weeks
Latanoprost monotherapy of 12weeks, Tafluprost monotherapy of 12weeks and if possible, continue monotherapy with either ophthalmic solution for 52weeks.
20 | years-old | <= |
Not applicable |
Male and Female
1. Diagnosed with normal-tension glaucoma
2. Person whose agreement is shown by him/herself
3. Over 20 years old on the date of agreement.
4. Both male and female
5. Outpatient treatment
6. Having latanoprost monotherapy treatment more than 4 weeks and whose intraocular pressure is between 10 mmHg and 21 mmHg.
7. Over 0.1 of corrected visual acuity with an eye for evaluation.
8. If both eyes can be evaluated, an eye with higher intraocular pressure will be chosen for evaluation.
1. Severe visual field defect (Ex:HFA <-15dB)
2. Any corneal abnormality or other condition preventing reliable applanation tonometry.
3. Presence of any external ocular disease, inflammation or infection of the eye and/or eyelids.
4. History of refractive surgery.
5. Diagnosed with degenerative miopia
6. History of laser trabeculoplasty, filtering surgery, trabeculotomy, or cataract surgery within 6 months.
7. Presence of any hypersensitivity to test drugs.
30
1st name | |
Middle name | |
Last name | Kazuhiko Mori |
Kyoto Prefectural University of Medicine
Department of ophthalmology
Hirokoji Kawaramachi Kamigyo-ku Kyoto 602-0841
1st name | |
Middle name | |
Last name | Kazuhiko Mori, Morio Ueno, Yoko Ikeda |
Kyoto Prefectural University of Medicine
Department of ophthalmology
075-251-5578
Department of ophthalmology, Kyoto Prefectural University of Medicine
None
Self funding
NO
2009 | Year | 06 | Month | 15 | Day |
Unpublished
Completed
2009 | Year | 05 | Month | 13 | Day |
2009 | Year | 06 | Month | 01 | Day |
2011 | Year | 08 | Month | 01 | Day |
2009 | Year | 05 | Month | 29 | Day |
2012 | Year | 06 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002460
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |